The prognostic significance of HER2 overexpression in non-small cell lung cancer

Anticancer Research

Volumn 31, Issue 12, 2011, Pages 4631-4636

  Takenaka, Masaru ^a   Hanagiri, Takeshi ^a   Shinohara, Shinji ^a   Kuwata, Taiji ^a   Chikaishi, Yasuhiro ^a   Oka, Soich ^a   Shigematsu, Yoshiki ^a   Nagata, Yoshika ^a   Shimokawa, Hidehiko ^a   Nakagawa, Makoto ^a   Uramoto, Hidetaka ^a   So, Tomoko ^a   Tanaka, Fumihiro ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

HER2; Immunohistochemical staining; Non small cell lung cancer; Prognosis; Surgical resection

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SCORING SYSTEM;

ADENOCARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; PROGNOSIS; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84855177600     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Akiyama T, Sudo C, Ogawara H, Toyoshima K and Yamamoto T: The product of the human c-erbB-2 gene: a 185-kilo-Dalton glycoprotein with tyrosine kinase activity. Science 232: 1644-1646, 1986. (Pubitemid 16095607)
2. Franklin WA, Veve R, Hirsch FR, Helfrich BA and Bunn PA Jr.: Epidermal growth factor receptor family in lung cancer and premalignancy. Semin Oncol 29: 3-14, 2002. (Pubitemid 34226514)
3. Szöllösi J, Balázs M, Feuerstein BG, Benz C and Waldman FM: ERBB-2 (HER2/neu) gene copy number, p185HER-2 over-expression, and intratumor heterogeneity in human breast cancer. Cancer Res 55: 5400-5407, 1995.
4. Koeppen HK, Wright BD, Burt AD, Quirke P, McNicol AM, Dybdal NO, Sliwkowski MX and Hillan KJ: Overexpression of HER2/neu in solid tumours: an immunohistochemical survey. Histopathology 38: 96-104, 2001. (Pubitemid 32194449)
5. Hendriks BS, Opresko LK, Wiley HS and Lauffenburger D: Quantitative analysis of HER2-mediated effects on HER2 and epidermal growth factor receptor endocytosis: distribution of homo- and heterodimers depends on relative HER2 levels. J Biol Chem 278: 23343-23345, 2003.
6. Grandal MV and Madshus IH: Epidermal growth factor receptor and cancer: control of oncogenic signalling by endocytosis. J Cell Mol Med 12: 1527-1534, 2008.
7. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK and ToGA Trial Investigators: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376: 687-97, 2010.
8. Dowsett M, Procter M, McCaskill-Stevens W, de Azambuja E, Dafni U, Rueschoff J, Jordan B, Dolci S, Abramovitz M, Stoss O, Viale G, Gelber RD, Piccart-Gebhart M and Leyland-Jones B: Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial. J Clin Oncol 27: 2962-2969, 2009.
9. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V, Sobin L and International Association for the Study of Lung Cancer International Staging Committee and Participating Institutions: The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2: 706-714, 2007.
10. Travis WD, Colby TV, Corrin B, Shimosato Y and Brambilla E (eds.). Histological type of lung and pleural tumors. World Health Organization International Histological Classification of Tumors, 3rd ed. Berlin: Springer, 1999.
11. Shimokawa H, Uramoto H, Onitsuka T, Iwata T, Nakagawa M, Ono K and Hanagiri T: TS expression predicts postoperative recurrence in adenocarcinoma of the lung. Lung Cancer 72: 360-364, 2011.
12. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, and Hayes DF: American Society of Clinical Oncology/College of American Pathologists Guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 131: 18-43, 2007. (Pubitemid 46174133)
13. Birner P, Oberhuber G, Stani J, Reithofer C, Samonigg H, Hausmaninger H, Kubista E, Kwasny W, Kandioler-Eckersberger D, Gnant M and Jakesz R: Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer. Clin Cancer Res 7: 1669-1675, 2001. (Pubitemid 32708634)
14. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
15. Goya T, Asamura H, Yoshimura H, Kato H, Shimokata K, Tsuchiya R, Sohara Y, Miya T, Miyaoka E and The Japanese Joint Committee of Lung Cancer Registry: Prognosis of 6644 resected non-small cell lung cancers in Japan: a Japanese lung cancer registry study. Lung Cancer 50: 227-234, 2005.
16. Hanagiri T, Baba T, So T, Yasuda M, Sugaya M, Ono K, So T, Uramoto H, Takenoyama M and Yasumoto K: Time trends of surgical outcome in patients with non-small cell lung cancer. J Thorac Oncol 5: 825-829, 2010.
17. Wagner TD and Yang GY: The role of chemotherapy and radiation in the treatment of locally advanced non-small cell lung cancer (NSCLC). Curr Drug Targets 11: 67-73, 2010.
18. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH and Eastern Cooperative Oncology Group: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346: 92-98, 2002.
19. Albarello L, Pecciarini L and Doglioni C: HER2 testing in gastric cancer. Adv Anat Pathol 18: 53-59, 2011.
20. Ugocsai K, Mándoky L, Tiszlavicz L and Molnár J: Investigation of HER2 overexpression in non-small cell lung cancer. Anticancer Res 25: 3061-3066, 2005. (Pubitemid 41044701)
21. Cox G, Vyberg M, Melgaard B Askaa J, Oster A and O'Byrne KJ: Herceptest: HER2 expression and gene amplification in non-small cell lung cancer. Int J Cancer 92: 480-483, 2001. (Pubitemid 32319419)
22. Perera SA, Li D, Shimamura T, Raso MG, Ji H, Chen L, Borgman CL, Zaghlul S, Brandstetter KA, Kubo S, Takahashi M, Chirieac LR, Padera RF, Branson RT, Shapiro GI, Greulich H, Meyerson M, Guertler U, Chesa PG, Solca F, Wistuba II and Wong KK: HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy. Proc Natl Acad Sci USA 106: 474-479, 2009.
23. Begnami MD, Fukuda E, Fregnani JH, Nonogaki S, Montagnini AL, da Costa WL Jr. and Soares FA: Prognostic Implications of Altered Human Epidermal Growth Factor Receptors (HERs) in Gastric Carcinomas: HER2 and HER3 Are Predictors of Poor Outcome. J Clin Oncol. 2011 Jun 27. [Epub ahead of print].
24. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182, 1987. (Pubitemid 17231334)
25. Nakamura H, Kawasaki N, Taguchi M and Kabasawa K: Association of HER-2 overexpression with prognosis in nonsmall cell lung carcinoma: a metaanalysis. Cancer 103: 1865-1873, 2005. (Pubitemid 40563259)
26. Pelosi G, Del Curto B, Dell'Orto P, Pasini F, Veronesi G, Spaggiari L, Maisonneuve P, Iannucci A, Terzi A, Lonardoni A and Viale G: Lack of prognostic implications of HER-2/neu abnormalities in 345 stage I non-small cell carcinomas (NSCLC) and 207 stage I-III neuroendocrine tumours (NET) of the lung. Int J Cancer 113: 101-108, 2005. (Pubitemid 39507316)
27. Tomizawa K, Suda K, Onozato R, Kosaka T, Endoh H, Sekido Y, Shigematsu H, Kuwano H, Yatabe Y and Mitsudomi T: Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancers. Lung Cancer 74: 139-144, 2011.
28. Shak S: Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group. Semin Oncol 26: 71-77, 1999.
29. Gatzemeier U, Groth G, Butts C, Van Zandwijk N, Shepherd F, Ardizzoni A, Barton C, Ghahramani P and Hirsh V: Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. Ann Oncol 15: 19-27, 2004. (Pubitemid 38139598)
30. Faber AC, Wong KK and Engelman JA: Differences underlying EGFR and HER2 oncogene addiction. Cell Cycle 9: 851-852, 2010.
31. Gilmer TM, Cable L, Alligood K, Rusnak D, Spehar G, Gallagher KT, Woldu E, Carter HL, Truesdale AT, Shewchuk L and Wood ER. Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib. Cancer Res 68: 571-579, 2008. (Pubitemid 351380086)
32. Swanton C, Futreal A and Eisen T: HER2-targeted therapies in non-small cell lung cancer. Clin Cancer Res 12: 4377s-4383s, 2006. (Pubitemid 44197185)